TrialThe Lancet. Haematology2019

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.

Matthew S Davids et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.